Top

American Journal of Clinical Dermatology

Published in:

01-04-2009 | Case Report

Efalizumab Therapy for Psoriasis in Patients with Inadequate Responses to Etanercept

Authors: Dr Jesse M. Kramer, James E. Turner

Published in: American Journal of Clinical Dermatology | Issue 2/2009

Abstract

Efalizumab is a recombinant humanized monoclonal antibody approved for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis. We present six cases of favorable response to efalizumab therapy in patients with psoriasis who demonstrated inadequate response or who were nonresponders to treatment with etanercept, a tumor necrosis factor-α-binding fusion protein. The subsequent response of these patients suggests that efalizumab may be a viable treatment option for patients with psoriasis who respond poorly to etanercept.

Jullien D, Prinz JC, Langley RGB, et al. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva™): mechanisms of action. Dermatology 2004; 208: 297–306

Krueger GG. Current concepts and review of alefacept in the treatment of psoriasis. Dermatol Clin 2004; 22 (4): 407–26, viiiPubMedCrossRef

Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152 (6): 1304–12PubMedCrossRef

Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, doubleblind trial. Lancet 2005; 366 (9494): 1367–74PubMedCrossRef

Gottlieb AB, Feldman S, Weinstein G, et al. Infliximab: one year results [poster no. P43]. 64th Annual Meeting of the American Academy of Dermatology; 2006 Mar 3-7; San Francisco (CA)

Langley R, Leonardi C, Toth D, et al. Long-term safety and efficacy of adalimumab in the treatment of moderate to severe chronic plaque psoriasis [abstract]. 14th European Academy of Dermatology and Venereology Congress; 2005 Oct 12-15; London

Tyring S, Poulin Y, Langley R, et al. A 96-week phase III study of safety and efficacy of etanercept 50mg twice weekly in patients with psoriasis [abstract]. J Am Acad Dermatol 2006; 54 Suppl. 3: AB10

Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003; 290 (23): 3073–80PubMedCrossRef

Menter A, Hamilton TK, Caro I, et al. Safety and tolerability of efalizumab therapy for patients with moderate to severe chronic plaque psoriasis: results of an open-label phase IIIb multicenter trial [abstract]. 63rd Annual Meeting of the American Academy of Dermatology; 2005 Feb 18-22; New Orleans (LA)

10.

Gottlieb AB, Gordon KB, Hamilton TK, et al. Maintenance of efficacy and safety with continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: final phase IIIb study results [abstract]. 63rd Annual Meeting of the American Academy of Dermatology; 2005 Feb 18-22; New Orleans (LA)

11.

Krueger GG, Feldman SR, Camisa C, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000; 43 (2 Pt 1): 281–5PubMedCrossRef

12.

Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol 2005; 152 (5): 861–7PubMedCrossRef

13.

Enbrel® (etanercept) [package insert]. Thousand Oaks (CA): Immunex Corporation, 2006 Apr

14.

Raptiva® (efalizumab) [package insert]. South San Francisco (CA): Genentech, Inc., 2005 Jun

Title: Efalizumab Therapy for Psoriasis in Patients with Inadequate Responses to Etanercept
Authors: Dr Jesse M. Kramer
James E. Turner
Publication date: 01-04-2009
Publisher: Springer International Publishing
Published in: American Journal of Clinical Dermatology / Issue 2/2009
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI: https://doi.org/10.2165/00128071-200910020-00008

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Efalizumab Therapy for Psoriasis in Patients with Inadequate Responses to Etanercept

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2009

Throwing a light on photosensitivity in atopic dermatitis

Periumbilical Purpura Prior to Gastrointestinal Involvement in Henoch-Schönlein Purpura

Role of Topical Calcineurin Inhibitors in the Treatment of Seborrheic Dermatitis

Clinical Implications of Aging Skin

Botulinum Toxin for Hyperhidrosis

Leukemic Phase of Follicular Lymphoma after Treatment with Etanercept in a Patient with Psoriasis